TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of High-Dose Acyclovir Versus Once Daily Valacyclovir on Herpes Simplex Virus Type 2 Genital Shedding in Herpes Simplex Virus-2 Seropositive Adults
Brief Summary: The purpose of the research study is to evaluate the effectiveness of high-dose acyclovir compared to valacyclovir for reduction of asymptomatic genital shedding in persons with genital herpes.

The study will enroll men and women who are 18 years or older, test positive to HSV-2 (by blood test) and have had a first outbreak of HSV-2 within the past 6 months or have had at least 4 genital herpes outbreaks in the past year. Participants must be HIV negative and willing to stop taking suppressive therapy for HSV for the one week wash out period. (Females only: You must not be pregnant or breast-feeding). Both men and women will be asked to use an effective form of birth control.

Involvement in the study will last 15-weeks and you will be asked to visit the clinic every 2-weeks. At each visit, you will be given medication to take daily (either valacyclovir or acyclovir; you will receive both medications at some point during this study). There will be a total of 9 study visits and each visit will last approximately 30 minutes. We will ask that you complete a daily symptom diary and collected daily home swabs 4-times a day, everyday during the study. Each daily home swab will take less than 3 minutes to perform.


Options:
A: Arm Label: Standard dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: valacyclovir | Arm Label: High-dose; Type: EXPERIMENTAL; Interventions: Drug: acyclovir | Intervention Type: DRUG; Name: acyclovir; Assigned to Arm(s): High-dose | Intervention Type: DRUG; Name: valacyclovir; Assigned to Arm(s): Standard dose
B: Arm Label: valacyclovir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valacyclovir | Arm Label: high dose valacyclovir; Type: EXPERIMENTAL; Interventions: Drug: valacyclovir | Intervention Type: DRUG; Name: valacyclovir; Assigned to Arm(s): high dose valacyclovir | Intervention Type: DRUG; Name: Valacyclovir; Assigned to Arm(s): valacyclovir
C: Intervention Type: DRUG; Name: Valacyclovir; Assigned to Arm(s): N/A
D: Arm Label: Arm 1 Male circumcision; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Male circumcision | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: Procedure: Male circumcision | Intervention Type: PROCEDURE; Name: Male circumcision; Assigned to Arm(s): Arm 1 Male circumcision, Arm 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of High-Dose Acyclovir Versus Once Daily Valacyclovir on Herpes Simplex Virus Type 2 Genital Shedding in Herpes Simplex Virus-2 Seropositive Adults
Brief Summary: The purpose of the research study is to evaluate the effectiveness of high-dose acyclovir compared to valacyclovir for reduction of asymptomatic genital shedding in persons with genital herpes.

The study will enroll men and women who are 18 years or older, test positive to HSV-2 (by blood test) and have had a first outbreak of HSV-2 within the past 6 months or have had at least 4 genital herpes outbreaks in the past year. Participants must be HIV negative and willing to stop taking suppressive therapy for HSV for the one week wash out period. (Females only: You must not be pregnant or breast-feeding). Both men and women will be asked to use an effective form of birth control.

Involvement in the study will last 15-weeks and you will be asked to visit the clinic every 2-weeks. At each visit, you will be given medication to take daily (either valacyclovir or acyclovir; you will receive both medications at some point during this study). There will be a total of 9 study visits and each visit will last approximately 30 minutes. We will ask that you complete a daily symptom diary and collected daily home swabs 4-times a day, everyday during the study. Each daily home swab will take less than 3 minutes to perform.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: acyclovir | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: acyclovir; Assigned to Arm(s): 1
B: Arm Label: Standard dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: valacyclovir | Arm Label: High-dose; Type: EXPERIMENTAL; Interventions: Drug: acyclovir | Intervention Type: DRUG; Name: acyclovir; Assigned to Arm(s): High-dose | Intervention Type: DRUG; Name: valacyclovir; Assigned to Arm(s): Standard dose
C: Arm Label: Famciclovir; Type: EXPERIMENTAL; Interventions: Drug: Famciclovir, Drug: Placebo matching valacyclovir | Arm Label: Valacyclovir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valacyclovir, Drug: Placebo matching famciclovir | Intervention Type: DRUG; Name: Famciclovir; Assigned to Arm(s): Famciclovir | Intervention Type: DRUG; Name: Valacyclovir; Assigned to Arm(s): Valacyclovir | Intervention Type: DRUG; Name: Placebo matching famciclovir; Assigned to Arm(s): Valacyclovir | Intervention Type: DRUG; Name: Placebo matching valacyclovir; Assigned to Arm(s): Famciclovir
D: Arm Label: valacyclovir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valacyclovir | Arm Label: high dose valacyclovir; Type: EXPERIMENTAL; Interventions: Drug: valacyclovir | Intervention Type: DRUG; Name: valacyclovir; Assigned to Arm(s): high dose valacyclovir | Intervention Type: DRUG; Name: Valacyclovir; Assigned to Arm(s): valacyclovir

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity Study of a DTaP-IPV-Hep B-PRP~T Combined Vaccine in Comparison to CombAct-HIB® Concomitantly Administered With Engerix B® Paediatric and OPV at 6, 10, and 14 Weeks of Age in South African Infants
Brief Summary: The purpose of this study is to document the immunological response to the investigational hexavalent vaccine at the 6, 10, and 14 weeks schedule

The primary objective is to demonstrate that the hexavalent DTaP-IPV-HB-PRP\~T combined vaccine does not induce lower immune responses than CombAct-HIB® with Engerix B® Paediatric and OPV in terms of seroprotection rates to Diphtheria (D), Tetanus (T), polio, Hepatitis B (HB), and Polyribosyl ribitol phosphate (PRP), one month after a 3-dose primary series (6, 10, and 14 weeks) with no HB vaccination at birth.

The secondary Objectives are:

To describe the safety in terms of any adverse events in the first 28 days after each injection and any serious adverse events during the entire trial.

To describe Immunogenicity after the primary series and prior to and after a booster vaccination.


Options:
A: Arm Label: Allergy Cases; Type: N/A; Interventions: N/A | Arm Label: Controls; Type: N/A; Interventions: N/A
B: Arm Label: Group 1: DTaP-IPV-Hep B-PRP-T; Type: EXPERIMENTAL; Interventions: Biological: DTaP-IPV-HB-PRP~T | Arm Label: Group 2: CombAct-HIB™ + OPV; Type: EXPERIMENTAL; Interventions: Biological: CombAct-HIB® | Arm Label: Group 3: DTaP-IPV-Hep B-PRP-T (ENGERIX B™ at birth); Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix B® Pediatric | Intervention Type: BIOLOGICAL; Name: DTaP-IPV-HB-PRP~T; Assigned to Arm(s): Group 1: DTaP-IPV-Hep B-PRP-T | Intervention Type: BIOLOGICAL; Name: CombAct-HIB®; Assigned to Arm(s): Group 2: CombAct-HIB™ + OPV | Intervention Type: BIOLOGICAL; Name: Engerix B® Pediatric; Assigned to Arm(s): Group 3: DTaP-IPV-Hep B-PRP-T (ENGERIX B™ at birth)
C: Arm Label: Group 1: DTaP-IPV-Hep B-PRP-T; Type: EXPERIMENTAL; Interventions: Biological: DTaP-IPV-HB-PRP~T | Arm Label: Group 2: Tritanrix-Hep B/Hib™+OPV; Type: ACTIVE_COMPARATOR; Interventions: Biological: Tritanrix-HepB/Hib | Intervention Type: BIOLOGICAL; Name: DTaP-IPV-HB-PRP~T; Assigned to Arm(s): Group 1: DTaP-IPV-Hep B-PRP-T | Intervention Type: BIOLOGICAL; Name: Tritanrix-HepB/Hib; Assigned to Arm(s): Group 2: Tritanrix-Hep B/Hib™+OPV
D: Arm Label: Phase A - SI; Type: EXPERIMENTAL; Interventions: Biological: Bordetella Pertussis B1917, Drug: Azithromycin 500 mg | Arm Label: Phase B Inoculum; Type: EXPERIMENTAL; Interventions: Biological: Bordetella Pertussis B1917, Drug: Azithromycin 500 mg | Arm Label: Phase B Sham; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin 500 mg, Other: Sterile Saline | Intervention Type: BIOLOGICAL; Name: Bordetella Pertussis B1917; Assigned to Arm(s): Phase A - SI, Phase B Inoculum | Intervention Type: DRUG; Name: Azithromycin 500 mg; Assigned to Arm(s): Phase A - SI, Phase B Inoculum, Phase B Sham | Intervention Type: OTHER; Name: Sterile Saline; Assigned to Arm(s): Phase B Sham

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Intramyocardial Injection of Autologous Bone-Marrow Cells in Patients With Severe, Chronic Ischemic Heart Disease Undergoing Coronary Bypass Surgery
Brief Summary: This study was designed to test the hypothesis that direct injection of bone-marrow cells in the heart may increase the number of blood vessels, ameliorating the heart's performance, and relieving patients from symptoms like angina and/or shortness of breath.


Options:
A: Arm Label: Treated Group; Type: EXPERIMENTAL; Interventions: Procedure: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation | Intervention Type: PROCEDURE; Name: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation; Assigned to Arm(s): Control Group, Treated Group
B: Arm Label: Autologous hMSCs; Type: ACTIVE_COMPARATOR; Interventions: Biological: Autologous hMSCs | Arm Label: Allogeneic hMSCs; Type: ACTIVE_COMPARATOR; Interventions: Biological: Allogeneic hMSCs | Intervention Type: BIOLOGICAL; Name: Autologous hMSCs; Assigned to Arm(s): Autologous hMSCs | Intervention Type: BIOLOGICAL; Name: Allogeneic hMSCs; Assigned to Arm(s): Allogeneic hMSCs
C: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Biological: Stem cell therapy | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Biological: Stem cell therapy | Intervention Type: BIOLOGICAL; Name: Stem cell therapy; Assigned to Arm(s): Group A, Group B
D: Intervention Type: PROCEDURE; Name: Intramyocardial injection of autologous bone marrow cells; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tai Chi Mind-Body Therapy for Knee Osteoarthritis: a Pilot Single-blind Randomized Controlled Trial
Brief Summary: The purpose of this study was to compare the safety and effectiveness of Tai Chi with an Attention Control intervention consisting of a stretching and wellness education program involving 40 patients with osteoarthritis (OA) of the knee. We hypothesized that the participants receiving Tai Chi would show greater improvement in knee pain, physical and psychological functioning, and health-related quality of life than participants in the Attention Control group, and that the benefit would be mediated by effects on muscle function, musculoskeletal flexibility and mental health.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral graded activity | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise therapy | Intervention Type: BEHAVIORAL; Name: Behavioral graded activity; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Exercise therapy; Assigned to Arm(s): B
B: Intervention Type: BEHAVIORAL; Name: Tai Chi classes; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Hydrotherapy classes; Assigned to Arm(s): N/A
C: Arm Label: Patient education; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Patient education and supervised exercise | Arm Label: Patient education and supervised exercise; Type: EXPERIMENTAL; Interventions: Procedure: Patient education and supervised exercise | Intervention Type: PROCEDURE; Name: Patient education and supervised exercise; Assigned to Arm(s): Patient education, Patient education and supervised exercise
D: Arm Label: Tai Chi; Type: EXPERIMENTAL; Interventions: Behavioral: Tai Chi versus Attention Control | Arm Label: Wellness Education and Stretching; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Tai Chi versus Attention Control | Intervention Type: BEHAVIORAL; Name: Tai Chi versus Attention Control; Assigned to Arm(s): Tai Chi, Wellness Education and Stretching

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: 9-10 Days Versus Prolonged Thromboprophylaxis in Patients Without Evidence of Ultrasound Proximal Thromboembolism After Total Knee Joint Replacement: a Randomized Controlled Trial
Brief Summary: The purpose of this study is to determine whether stopping Low Molecular Weight Heparin (LMWH) thromboprophylaxis is safe after total knee joint replacement. The investigators select patients without proximal thromboembolism assessed by bilateral venous ultrasound examination 7-10 days after surgery. the investigators hypothesis is that stopping thromboprophylaxis is equally effective than prolonging thromboprophylaxis in order to prevent post-surgery complications in this population.


Options:
A: Arm Label: dabigatran etexilate 75 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate | Arm Label: dabigatran etexilate 110 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate | Arm Label: enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: enoxaparin | Intervention Type: DRUG; Name: dabigatran etexilate; Assigned to Arm(s): dabigatran etexilate 75 mg | Intervention Type: DRUG; Name: dabigatran etexilate; Assigned to Arm(s): dabigatran etexilate 110 mg | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): enoxaparin
B: Arm Label: Apixaban, 2.5 mg BID plus placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban, Drug: Enoxaparin-matching placebo | Arm Label: Enoxaparin, 40 mg QD plus placebo; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin, Drug: Apixaban-matching placebo | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin, 40 mg QD plus placebo | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban, 2.5 mg BID plus placebo | Intervention Type: DRUG; Name: Enoxaparin-matching placebo; Assigned to Arm(s): Apixaban, 2.5 mg BID plus placebo | Intervention Type: DRUG; Name: Apixaban-matching placebo; Assigned to Arm(s): Enoxaparin, 40 mg QD plus placebo
C: Intervention Type: DRUG; Name: EXANTA; Assigned to Arm(s): N/A
D: Intervention Type: PROCEDURE; Name: Bilateral ultrasound examination 7+/- 2 after surgery; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin C and Vitamin E Therapy in Type 2 Diabetes and Cardiovascular Risk
Brief Summary: The proposed study will examine the hypothesis that vitamin C and vitamin E given to type 2 diabetic individuals will provide effective anti-inflammatory, anti-thrombotic, and anti-oxidative atherosclerotic protection when administered at the optimal dose as determined by surrogate markers of inflammation, hypercoagulability, and oxidation.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Vitamin C, and Alpha-lipoic Acid, Drug: Placebo wafers | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Coenzyme Q, Drug: Placebo capsules | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules, Drug: Placebo wafers | Intervention Type: DRUG; Name: Vitamin E, Vitamin C, and Alpha-lipoic Acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Coenzyme Q; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): 2, 3 | Intervention Type: DRUG; Name: Placebo wafers; Assigned to Arm(s): 1, 3
B: Intervention Type: BEHAVIORAL; Name: ascorbic acid, vitamin E, beta carotene, selenium, zinc; Assigned to Arm(s): N/A
C: Arm Label: MRI(+ve),; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: 200mg of Palm vitamin E (tocotrienols) or placebo | Arm Label: MRI(-ve); Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: 200mg of Palm vitamin E (tocotrienols) or placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 200mg of Palm vitamin E (tocotrienols) or placebo; Assigned to Arm(s): MRI(+ve),, MRI(-ve)
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Study Arm A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Study Arm B | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Study Arm C | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Study Arm D | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm A; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm B; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm C; Assigned to Arm(s): 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm D; Assigned to Arm(s): 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin C and Vitamin E Therapy in Type 2 Diabetes and Cardiovascular Risk
Brief Summary: The proposed study will examine the hypothesis that vitamin C and vitamin E given to type 2 diabetic individuals will provide effective anti-inflammatory, anti-thrombotic, and anti-oxidative atherosclerotic protection when administered at the optimal dose as determined by surrogate markers of inflammation, hypercoagulability, and oxidation.


Options:
A: Arm Label: Vitamin E + selenium placebo; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Other: selenium placebo | Arm Label: Selenium + vitamin E placebo; Type: EXPERIMENTAL; Interventions: Drug: Selenium, Other: Vitamin E placebo | Arm Label: Vitamin E + selenium; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Drug: Selenium | Arm Label: Vitamin E placebo + selenium placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Vitamin E placebo, Other: selenium placebo | Intervention Type: DRUG; Name: Vitamin E; Assigned to Arm(s): Vitamin E + selenium, Vitamin E + selenium placebo | Intervention Type: DRUG; Name: Selenium; Assigned to Arm(s): Selenium + vitamin E placebo, Vitamin E + selenium | Intervention Type: OTHER; Name: Vitamin E placebo; Assigned to Arm(s): Selenium + vitamin E placebo, Vitamin E placebo + selenium placebo | Intervention Type: OTHER; Name: selenium placebo; Assigned to Arm(s): Vitamin E + selenium placebo, Vitamin E placebo + selenium placebo
B: Arm Label: Ginkgo Synergy® and Choline; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ginkgo Synergy® and Choline | Arm Label: OPC Synergy® and Catalyn; Type: EXPERIMENTAL; Interventions: Dietary Supplement: OPC Synergy® and Catalyn | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Ginkgo Synergy® and Choline; Assigned to Arm(s): Ginkgo Synergy® and Choline | Intervention Type: DIETARY_SUPPLEMENT; Name: OPC Synergy® and Catalyn; Assigned to Arm(s): OPC Synergy® and Catalyn | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: BEHAVIORAL; Name: ascorbic acid, vitamin E, beta carotene, selenium, zinc; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Study Arm A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Study Arm B | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Study Arm C | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Study Arm D | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm A; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm B; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm C; Assigned to Arm(s): 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm D; Assigned to Arm(s): 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin C and Vitamin E Therapy in Type 2 Diabetes and Cardiovascular Risk
Brief Summary: The proposed study will examine the hypothesis that vitamin C and vitamin E given to type 2 diabetic individuals will provide effective anti-inflammatory, anti-thrombotic, and anti-oxidative atherosclerotic protection when administered at the optimal dose as determined by surrogate markers of inflammation, hypercoagulability, and oxidation.


Options:
A: Arm Label: Vitamin E + selenium placebo; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Other: selenium placebo | Arm Label: Selenium + vitamin E placebo; Type: EXPERIMENTAL; Interventions: Drug: Selenium, Other: Vitamin E placebo | Arm Label: Vitamin E + selenium; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Drug: Selenium | Arm Label: Vitamin E placebo + selenium placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Vitamin E placebo, Other: selenium placebo | Intervention Type: DRUG; Name: Vitamin E; Assigned to Arm(s): Vitamin E + selenium, Vitamin E + selenium placebo | Intervention Type: DRUG; Name: Selenium; Assigned to Arm(s): Selenium + vitamin E placebo, Vitamin E + selenium | Intervention Type: OTHER; Name: Vitamin E placebo; Assigned to Arm(s): Selenium + vitamin E placebo, Vitamin E placebo + selenium placebo | Intervention Type: OTHER; Name: selenium placebo; Assigned to Arm(s): Vitamin E + selenium placebo, Vitamin E placebo + selenium placebo
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Study Arm A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Study Arm B | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Study Arm C | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Study Arm D | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm A; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm B; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm C; Assigned to Arm(s): 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm D; Assigned to Arm(s): 4
C: Arm Label: PGZ; Type: EXPERIMENTAL; Interventions: Drug: pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): PGZ | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: BEHAVIORAL; Name: ascorbic acid, vitamin E, beta carotene, selenium, zinc; Assigned to Arm(s): N/A

Answer: B